N/A N=60 Randomized Triple-blind Treatment

Korean Red Ginseng and Metabolic Syndrome

Metabolic Syndrome

Bottom Line

View on ClinicalTrials.gov: NCT00976274 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Feb 2012

Primary outcome: Primary: Change in the Pre- and Post-treatment Systolic Blood Pressure — 129.5; 134.5; 122.6; 127.5 mm Hg

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Korean red ginseng (Dietary_supplement); starch (Dietary_supplement)
Age: Adult, Older Adult · 20+ yrs
Sex: All
Sponsor: The Korean Society of Ginseng
Primary completion: Jan 2011

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in the Pre- and Post-treatment Systolic Blood Pressure	129.5; 134.5; 122.6; 127.5	—
SECONDARY Change in the Pre- and Post-treatment Oxidized Low-densty Lipoprotein(LDL)	83.3; 78.8; 83.4; 76.3	—

Summary

Five factor consisting of Metabolic syndrome is closely linked by insulin resistance. Until now, several studies have been performed about effects of Korea red ginseng on hypertension, diabetes, and hyperlipidemia, but not metabolic syndrome. The investigators hypothesize that Korean red ginseng could improve each constituents of metabolic syndrome, arterial stiffness, and inflammatory markers. The aim of this study is to determine effects of Korean red ginseng on cardiovascular risks in subjects with metabolic syndrome.

Eligibility Criteria

Inclusion Criteria:(three or more of following five factors)

waist circumference(male: more than 90cm, female: more than 80cm)
blood pressure(systolic: more than 130mmHg, diastolic: more than 85mmHg)
fasting plasma glucose: more than 100mg/dL
fasting triglycerides: more than 150mg/dL
High-density lipoprotein(HDL)-cholesterol(male: less than 40mg/dL, female: less than 50mg/dL)

Exclusion Criteria: (any one of following factors)

uncontrolled blood pressure(systolic: more than 160mmHg, diastolic: more than 100mmHg) or subjects taking blood pressure lowering drug
Type 2 diabetes patients or fasting plasma glucose more than 126mg/dL
triglyceride more than 400mg/dL, total cholesterol more than 250mg/dL
subjects taking antilipidemic drug
past history of coronary heart disease or cerebrovascular disease

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00976274). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.